Myelin oligodendrocyte glycoprotein transduced T cell therapy - ImCyse

Drug Profile

Myelin oligodendrocyte glycoprotein transduced T cell therapy - ImCyse

Alternative Names: MOG autologous T-lymphocyte cell therapy - ImCyse; MOG cytolytic CD4+ T-cell therapy - ImCyse; MOG gene therapy - ImCyse; MOG peptide gene therapy - ImCyse; MOG transduced T-cells - ImCyse; MOG-autologous CD4+ cell therapy - ImCyse; Myelin oligodendrocyte glycoprotein gene therapy - ImCyse; Myelin oligodendrocyte glycoprotein transduced T-cells - ImCyse

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImCyse
  • Developer GlaxoSmithKline; ImCyse; Rega Institute for Medical Research; Trinity College Dublin
  • Class Anti-inflammatories; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunosuppressants; Myelin-oligodendrocyte glycoprotein expression stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Type 1 diabetes mellitus
  • Preclinical Multiple sclerosis
  • Research Cancer; Infections; Myasthenia gravis; Rheumatoid arthritis
  • Discontinued Asthma; Graft-versus-host disease

Most Recent Events

  • 22 Aug 2017 Discontinued - Preclinical for Asthma in Belgium (unspecified route)
  • 22 Aug 2017 Discontinued - Preclinical for Graft-versus-host disease in Belgium (unspecified route)
  • 22 Aug 2017 Early research in Infections in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top